V-Edge: Virtual Edge Computing as an Enabler for Novel Microservices and Cooperative Computing

As we move from 5G to 6G, edge computing is one of the concepts that needs revisiting. Its core idea is still intriguing: Instead of sending all data and tasks from an end user's device to the cloud, possibly covering thousands of kilometers and introducing delays lower-bounded by propagation speed, edge servers deployed in close proximity to the user (e.g., at some base station) serve as proxy for the cloud. This is particularly interesting for upcoming machine-learning-based intelligent services, which require substantial computational and networking performance for continuous model training. However, this promising idea is hampered by the limited number of such edge servers. In this article, we discuss a way forward, namely the V-Edge concept. V-Edge helps bridge the gap between cloud, edge, and fog by virtualizing all available resources including the end users' devices and making these resources widely available. Thus, V-Edge acts as an enabler for novel microservices as well as cooperative computing solutions in next-generation networks. We introduce the general V-Edge architecture, and we characterize some of the key research challenges to overcome in order to enable wide-spread and intelligent edge services

V-Edge: Virtual Edge Computing as an Enabler for Novel Microservices and Cooperative Computing

As we move from 5G to 6G, edge computing is one of the concepts that needs revisiting. Its core idea is still intriguing: instead of sending all data and tasks from an end user's device to the cloud, possibly covering thousands of kilometers and introducing delays that are just owed to limited propagation speed, edge servers deployed in close proximity to the user, e.g., at some 5G gNB, serve as proxy for the cloud. Yet this promising idea is hampered by the limited availability of such edge servers. In this paper, we discuss a way forward, namely the virtual edge computing (V-Edge) concept. V-Edge bridges the gap between cloud, edge, and fog by virtualizing all available resources including the end users' devices and making these resources widely available using well-defined interfaces. V-Edge also acts as an enabler for novel microservices as well as cooperative computing solutions. We introduce the general V-Edge architecture and we characterize some of the key research challenges to overcome, in order to enable wide-spread and even more powerful edge services

Stakeholder engagement to ensure the sustainability of biobanks: a survey of potential users of biobank services

Biobanks are important infrastructures facilitating biomedical research. After a decade of rolling out such infrastructures, a shift in attention to the sustainability of biobanks could be observed in recent years. In this regard, an increase in the as yet relatively low utilisation rates of biobanks has been formulated as a goal. Higher utilisation rates can only be achieved if the perspectives of potential users of biobanks-particularly researchers not yet collaborating with biobanks-are adequately considered. To better understand their perspectives, a survey was conducted at ten different research institutions in Germany hosting a centralised biobank. The survey targeted potential users of biobank services, i.e. researchers working with biosamples. It addressed the general demand for biosamples, strategies for biosample acquisition/storage and reasons for/against collaborating with biobanks. In total, 354 researchers filled out the survey. Most interestingly, only a minority of researchers (12%) acquired their biosamples via biobanks. Of the respondents not collaborating with biobanks on sample acquisition, around half were not aware of the (services of the) respective local biobank. Those who actively decided against acquiring biosamples via a biobank provided different reasons. Most commonly, respondents stated that the biosamples required were not available, the costs were too high and information about the available biosamples was not readily accessible. Biobanks can draw many lessons from the results of the survey. Particularly, external communication and outreach should be improved. Additionally, biobanks might have to reassess whether their particular collection strategies are adequately aligned with local researchers' needs

A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

BACKGROUND: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period. METHODOLOGY/PRINCIPAL FINDINGS: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012). CONCLUSIONS: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction. TRIAL REGISTRATION: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616

Quartet, strings, F minor

Reproduced from manuscript. --- For 2 violins, viola & violoncello

Carbon-14 labeling of D 16 427, a new positive inotropic compound

The title compd. I [ring A (U)-14C-labeled] was prepd. in 8 steps starting by acylating (U)-14C-ring labeled PhMe with EtCOCl

[Impact of tobacco use on the periodontium--an update (I)--Part 1: Epidemiologic und pathogenetic aspects of tobacco-related periodontal diseases]

This literature review represents the second in a series of articles from the Swiss task force "Smoking--Intervention in the private dental office" on the topic "tobacco use and dental medicine". In this article, the epidemiological background as well as some pathogenetic processes are described and discussed critically for tobacco-related periodontal diseases. Earlier publications confirmed tobacco consumption as a risk factor for periodontal diseases. Over the last few years, oral health research has significantly contributed to the understanding of the mechanisms leading to the deterioration of the hard and soft tissues supporting the teeth. With the recording of the number of cigarettes smoked per day and the amount of years tobacco was used, a dose response relationship was established. Various, potentially significant pathogenic effects of tobacco-related substances may exist on the periodontal tissues, the immune response system or the composition of the oral flora. Moreover, there is reference that tobacco consumption may change the genetically determined susceptibility for periodontal diseases

Tobacco use prevention and cessation in the dental practice

This is the fourth part of a series of publications from the Swiss task force named "Smoking--intervention in the private dental office" on the topic "tobacco use and dental medicine". It presents the implementation of tobacco use prevention and cessation in the dental practice. Next to the optimal performance of plaque control, tobacco use cessation has become the most important measure for the treatment of periodontal diseases. In contrast to general medicine practice, the dental practice team is seeing its patients regularly and is therefore capable of helping their patients quit tobacco use. Tobacco dependence consists of both a physical and a psychological dependence. Therefore, the combination of pharmacotherapy with behavior change counseling is recommended. The use of brief Motivational Interviewing (BMI) for tobacco use short interventions in the dental practice appears to be suitable. Nicotine replacement therapy (NRT) is the treatment of choice for the dental practice team because both Varenicline and Bupropion SR have to be prescribed by physicians.Link_to_subscribed_fulltex